Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression

Innate Immunity

Volumn 15, Issue 1, 2009, Pages 33-41

  Noman, Abu Shadat M ^a   Koide, Naoki ^a   Hassan, Ferdaus ^a   I E Khuda, Imtiaz ^a   Dagvadorj, Jargalsaikhan ^a   Tumurkhuu, Gantsetseg ^a   Islam, Shamima ^a   Naiki, Yoshikazu ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

LPS; MyD88; RAW 264.7 cells; Thalidomide; TNF

Indexed keywords

CD14 ANTIGEN; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD14; CELL LINE; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DOWN-REGULATION; I-KAPPA B PROTEINS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUPEPTINS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; THALIDOMIDE; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 59849096576     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908099317     Document Type: Article

References (34)

1. Hideshima T., Chauhan D., Schlossman R. et al. The role of tumor necrosis factor-α in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20: 4519-4527.
2. Eisen T., Boshoff C., Mak I. et al. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812-817.
3. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
4. Haslett PA, Corral LG, Albert M. et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892.
5. Zwingenberger K., Wnendt S. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J Inflamm 1995; 46: 177-211.
6. Sampaio EP, Sarno EN, Galilly R. et al. Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
7. Moreira AL, Sampaio EP, Zmuidzinas A. et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
8. Paul SC, Lv P., Xiao YJ et al. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology 2006; 73: 82-92.
9. Ishikawa M., Kanno S., Takayanagi M. et al. Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice. Biol Pharm Bull 1998; 21: 638-640.
10. Kawai T., Adachi O., Ogawa T. et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-122.
11. Shakhov AN, Collart MA, Vassalli P. et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 1990; 171: 35-47.
12. Saklatvala J., Davis W., Guesdon F. Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Philos Trans R Soc Lond B Biol Sci 1996; 351: 151-157.
13. Han J., Lee JD, Bibbs L. et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-811.
14. Hambleton J., Weinstein SL, Lem L. et al. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA 1996; 93: 2774-2778.
15. Herrera-Velit P., Reiner NE Bacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. J Immunol 1996; 156: 1157-1165.
16. Chakravortty D., Kato Y., Sugiyama T. et al. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: A role of Raf-1 in lipopolysaccharide signaling. J Immunol 2001; 166: 2011-2017.
17. Naiki Y., Michelsen KS, Zhanq W. et al. Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM-and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem 2005; 280: 5491-5495.
18. Keifer JA, Guttridqe DC, Ashburner BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-22387.
19. Zandi E., Rothwarf DM, Delhase M. et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for NF-kappaB activation. Cell 1997; 91: 243-252.
20. Scheidereit C. Signal transduction: Docking IKB kinases. Nature 1998; 395: 225-226.
21. Ozes ON, Mayo LD, Gustin JA et al. NF-KB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
22. Ozes ON, Mayo LD, Gustin JA et al. Reply: Kinase regulation in inflammatory response. Nature 2000; 406: 368-368.
23. Yamamoto M., Sato S., Hemmi H. et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329.
24. Akira S., Takeda K. Toll-like receptor in innate immunity. Int Immunol 2005; 1: 1-14.
25. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
26. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3: 20-26.
27. Lv P., Luo HS, Zhou XP et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res 2007; 38: 15-27.
28. Chauhan D., Hideshima T., Mitsiades C. et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005; 4: 686-692.
29. Roodman GD Bone building with bortezomib. J Clin Invest 2008; 118: 462-464.
30. von Metzler I., Krebbel H., Hecht M. et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.
31. Kopp EB, Medzitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999; 11: 13-18.
32. Dziarski R., Gupta D. Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes. J Endotoxin Res 2000; 6: 401-405.
33. Chen CS, Perng WC, Chen CW et al. Thalidomide reduces lipopolysaccharide/ zymosan-induced acute lung injury in rats. J Biomed Sci 2004; 11: 591-598.
34. Enomoto N., Takei Y., Hirose M. et al. Protective effect of thalidomide on endotoxin-induced liver injury. Alcohol Clin Exp Res 2003; 27: 2S-6S.